[go: up one dir, main page]

PE20151774A1 - Construcciones de proteinas mitocondriales y sus usos - Google Patents

Construcciones de proteinas mitocondriales y sus usos

Info

Publication number
PE20151774A1
PE20151774A1 PE2015002144A PE2015002144A PE20151774A1 PE 20151774 A1 PE20151774 A1 PE 20151774A1 PE 2015002144 A PE2015002144 A PE 2015002144A PE 2015002144 A PE2015002144 A PE 2015002144A PE 20151774 A1 PE20151774 A1 PE 20151774A1
Authority
PE
Peru
Prior art keywords
constructions
disclosed
mitochondrial proteins
mitochondrial
mitochondria
Prior art date
Application number
PE2015002144A
Other languages
English (en)
Inventor
Hagar Greif
Haya Lorberboum-Galski
Original Assignee
Bio Blast Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Blast Pharma Ltd filed Critical Bio Blast Pharma Ltd
Publication of PE20151774A1 publication Critical patent/PE20151774A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0091—Oxidoreductases (1.) oxidizing metal ions (1.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1018—Carboxy- and carbamoyl transferases (2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Se divulgan construcciones de proteinas de fusion que comprenden una proteina mitocondrial funcional, que pueden ingresar a la mitocondria dentro de las celulas intactas. Ademas, se divulgan metodos de tratamiento de trastornos mitocondriales con las proteinas de fusion divulgadas y composiciones correspondientes
PE2015002144A 2013-04-15 2014-04-10 Construcciones de proteinas mitocondriales y sus usos PE20151774A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811934P 2013-04-15 2013-04-15
US201361869981P 2013-08-26 2013-08-26
US14/034,224 US8912147B2 (en) 2013-04-15 2013-09-23 Mitochondrial proteins constructs and uses thereof

Publications (1)

Publication Number Publication Date
PE20151774A1 true PE20151774A1 (es) 2015-12-20

Family

ID=51686951

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002144A PE20151774A1 (es) 2013-04-15 2014-04-10 Construcciones de proteinas mitocondriales y sus usos

Country Status (13)

Country Link
US (1) US8912147B2 (es)
EP (1) EP2986629B1 (es)
JP (1) JP2016520557A (es)
KR (1) KR20150143778A (es)
AU (1) AU2014255313A1 (es)
BR (1) BR112015026017A2 (es)
CA (1) CA2909276A1 (es)
EA (1) EA201501028A1 (es)
MD (1) MD20150109A2 (es)
MX (1) MX2015014424A (es)
PE (1) PE20151774A1 (es)
SG (1) SG11201508313TA (es)
WO (1) WO2014170896A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180132833A (ko) 2016-04-12 2018-12-12 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. Mcm 결핍과 관련된 장애의 치료를 위한 메틸말로닐 조효소 a 뮤타아제 (mcm) 융합 구조체
GB201721833D0 (en) * 2017-12-22 2018-02-07 Cancer Research Tech Ltd Fusion proteins
US20220096520A1 (en) * 2018-12-06 2022-03-31 Arcturus Therapeutics, Inc. Modified proteins and associated methods of treatment
ES2960692T3 (es) * 2018-12-06 2024-03-06 Arcturus Therapeutics Inc Composiciones y métodos para el tratamiento de la deficiencia de ornitina transcarbamilasa
CN110003345A (zh) * 2019-04-03 2019-07-12 天津师范大学 一种抗迟缓爱德华氏菌的TAT-EseD重组蛋白及用途
EP3999102A1 (en) 2019-07-18 2022-05-25 Larimar Therapeutics, Inc. Use of frataxin for treating leigh syndrome, french canadian type
AU2020321901A1 (en) 2019-07-29 2022-02-24 The Trustees Of Indiana University Materials and methods for treating Friedreich's Ataxia
AU2020391489A1 (en) 2019-11-25 2022-06-09 Larimar Therapeutics, Inc. Methods for quantifying frataxin activity
EP4114470A4 (en) 2020-03-03 2024-04-17 Arcturus Therapeutics, Inc. Compositions and methods for the treatment of ornithine transcarbamylase deficiency
CN115843269A (zh) * 2020-03-26 2023-03-24 拉利玛生物医药公司 用于细胞器特异性蛋白递送的分子
CA3176208A1 (en) 2020-04-30 2021-11-04 Joan David Bettoun Methods for treating myelin associated diseases and mitochondria associated diseases
CN116867506A (zh) 2020-12-12 2023-10-10 拉利玛生物医药公司 包括弗里德赖希共济失调蛋白融合蛋白的药物组合物及其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042560A2 (en) * 2003-10-24 2005-05-12 Wake Forest University Health Sciences Non-viral delivery of compounds to mitochondria
ES2560097T3 (es) 2008-02-04 2016-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Procedimientos y composiciones de tratamiento de trastornos mitocondriales

Also Published As

Publication number Publication date
US8912147B2 (en) 2014-12-16
MD20150109A2 (ro) 2016-03-31
US20140308262A1 (en) 2014-10-16
KR20150143778A (ko) 2015-12-23
EP2986629B1 (en) 2017-11-08
EP2986629A2 (en) 2016-02-24
WO2014170896A3 (en) 2014-12-31
SG11201508313TA (en) 2015-11-27
AU2014255313A1 (en) 2015-09-10
JP2016520557A (ja) 2016-07-14
CA2909276A1 (en) 2014-10-23
EA201501028A1 (ru) 2016-04-29
WO2014170896A2 (en) 2014-10-23
MX2015014424A (es) 2016-05-18
BR112015026017A2 (pt) 2017-10-17

Similar Documents

Publication Publication Date Title
PE20151774A1 (es) Construcciones de proteinas mitocondriales y sus usos
CL2024003234A1 (es) Polipéptidos modificados y usos de los mismos.
IL262652A (en) Gdf15 fusion proteins and uses thereof
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CL2018000457A1 (es) Anticuerpos anti-mesotelina completamente humanos y células con efecto inmune dirigido a la mesotelina
MX394528B (es) Esteroides y conjugados de proteinas de los mismos.
CL2018001565A1 (es) Inmunoglobulinas conjugadas con lisina c-terminal
PL3423105T3 (pl) Koniugaty przeciwciało-lek oparte na erybulinie i sposoby zastosowania
EP3585418A4 (en) CHEMICAL PROTEINS FORMED FROM TIGIT AND LIGHT
CL2019002605A1 (es) Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas.
MX2017009153A (es) Proteinas de fusion de citoquinas.
MA50908A (fr) Formulations de protéines de fusion vegfr-fc
MX2017002469A (es) Composiciones de matrices extracelulares.
GT201500014S (es) Diseño de botella
CY1124727T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
MX2017011194A (es) Anticuerpos, usos y métodos.
MX377780B (es) Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
MA49414A (fr) Protéines de fusion de dmdv et e2 et leurs utilisations
EP3688037A4 (en) IMMUNOMODULATOR FUSION PROTEINS
EP3801605A4 (en) STABLE FUSION PROTEIN FORMULATION
DK3697804T5 (da) REKOMBINANT EKSPRESSION AF PCV2b-ORF2-PROTEIN I INSEKTCELLER
MX2016015615A (es) Control de la formacion de enlaces disulfuro en disoluciones de proteinas mediante la adicion de agentes reductores.
DK3197046T3 (da) Selvforspændt output booster forstærker samt anvendelse deraf
MX2019001077A (es) Solucion acuosa cristaloide isotonica.
EP3893833C0 (fr) Gelée de parfum

Legal Events

Date Code Title Description
FA Abandonment or withdrawal